Scinopharm
Scinopharm, officially known as Scinopharm Taiwan, is a leading player in the pharmaceutical industry, headquartered in Taiwan (TW). Founded in 1997, the company has established a strong presence in the global market, particularly in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. With a focus on high-quality production and innovative solutions, Scinopharm has achieved significant milestones, including regulatory approvals from major health authorities. Their core offerings include a diverse range of APIs, particularly for oncology and cardiovascular treatments, distinguished by their commitment to quality and sustainability. Recognised for its robust research and development capabilities, Scinopharm has positioned itself as a trusted partner in the pharmaceutical supply chain, contributing to advancements in healthcare worldwide.
DitchCarbon Score
How does Scinopharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Scinopharm's score of 13 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Scinopharm's reported carbon emissions
In 2023, Scinopharm reported total carbon emissions of approximately 21,360,510 kg CO2e, comprising 4,292,540 kg CO2e from Scope 1 and 17,067,970 kg CO2e from Scope 2 emissions. This reflects a commitment to reducing their carbon footprint, with a target to achieve a 10-15% reduction in carbon dioxide emissions per unit of logistics by 2025, compared to 2022 levels. Over the years, Scinopharm has demonstrated a significant reduction in emissions. For instance, in 2012, their total emissions were about 23,846,000 kg CO2e, which decreased to approximately 21,360,510 kg CO2e by 2023. This indicates a proactive approach to managing their environmental impact within the pharmaceutical sector. The company has not yet committed to a net-zero target but remains focused on improving efficiency and reducing emissions across all scopes. Their initiatives are aligned with industry standards, reflecting a growing awareness of climate responsibilities in the biotechnology and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 7,158,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 16,689,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Scinopharm is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
